Vivos Inc. RDGL

Company Overview

Vivos Inc. (NASDAQ: RDGL), formerly known as RadioGel™, is a U.S.-based medical device company focused on developing minimally invasive radiotherapy technologies for the treatment of solid tumors. The company operates within the oncology and medical isotope sectors, with its primary commercial and development focus centered on injectable brachytherapy treatments using radioactive isotopes. Its lead product candidate, RadioGel™, is designed to deliver localized beta radiation directly into tumors through a hydrogel-based delivery system intended to limit radiation exposure to surrounding healthy tissue.

The company’s core business strategy is based on advancing proprietary isotope delivery technologies for veterinary and human oncology applications. Vivos has historically concentrated on companion animal cancer treatment as a pathway toward broader human therapeutic applications and regulatory advancement. The company evolved from earlier development-stage operations focused on isotope therapeutics and rebranded around the RadioGel platform as it refined its commercialization and regulatory strategy. Public disclosures and investor materials indicate that Vivos positions itself as a niche participant in localized cancer therapy with emphasis on precision treatment, outpatient administration potential, and reduced invasiveness compared with conventional surgery or external beam radiation.